Is Veraxa Biotech Holding AG (VRXA) a Buy, Sell, or Hold?
NASDAQ : VRXA
Veraxa Biotech Holding AG
$1.9701 USD
-$0.04 (-1.99%)
- Volume
- 255.84K
- Average Volume
- 418.16K
- Market Capitalization
- $278.59M
- P/E Ratio
- Dividend Yield
- %
- Price Target
- Year High
- $27.36
- Year Low
- $1.70
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
Company Overview
NASDAQ
Christoph Antz
Biotechnology
Healthcare
VRXA
8
DE
USD
Liquidity Metrics
Sales & Valuation
-$
Profitability
-$
%
%
%
%
P/E Metrics
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
No financial score data available.
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Christoph Antz | Co-Founder, Lead Director & CEO |
| Christoph Erkel | Vice President of Research & Development |
| Heinz Schwer | Chief Business Officer |
| Rick Austin | Chief Scientific Officer |
| Torsten Bürgermeister | Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Veraxa Biotech Holding AG (NASDAQ:VRXA) Stock
Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp., focusing on developing next-generation cancer therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers. [64, 65] ...
2026-07-27 07:00:00
VERAXA Biotech's and OmniAb's bispecific ADC program VXA-222 advances into next phase at VERAXA following the achievement of a key technical milestone.
2026-07-27 07:00:00
ZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies, today announced the advancement of bispecific ADC (bsADC) program VXA-222, following successful achievement of a key technical milestone in its alliance with OmniAb, Inc.
2026-07-24 16:05:00
ZURICH, SWITZERLAND , July 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in the design and development of next-generation cancer therapeutics, held an Extraordinary General Meeting (EGM) today. All resolutions proposed by the Board of Directors and previously communicated in the company's July 2, 2026 shareholder materials were approved by an overwhelming majority of more than 99.94% of the shareholders present or represented at the meeting.
2026-07-23 07:00:00
ZURICH, SWITZERLAND, July 23, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the appointment of Christoph Erkel, Ph.D., as Chief Scientific Officer (CSO), effective immediately. Christoph Erkel, previously Vice President of Research & Development at VERAXA, will apply his extensive management expertise in R&D to direct and accelerate development of the company's proprietary BiTAC® (bi-targeted tumor-associated cytotoxicity) platform technologies, with the goal of developing safer and more effective cancer treatments for patients with solid tumors. He succeeds Rick Austin, Ph.D., who will be leaving the company after a successful transition period.
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
2026-07-20 07:00:00
ZURICH, SWITZERLAND – July 20, 2026 – VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA), an emerging leader in designing novel cancer therapies, today announced that it has received Scientific Advice from the German regulatory authority, the Paul-Ehrlich-Institute (PEI), regarding the underlying biology and proposed non-clinical development plan for its most-advanced development program based on its proprietary BiTAC-TCE technology. In the PEI's Scientific Advice procedure, drug developers can consult with regulatory experts on how to best evaluate their new drug candidates with a key focus on safety and tolerability.
2026-07-13 07:00:00
ZURICH, SWITZERLAND - July 13, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA"), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S. A. , an AI-driven computational partner for modern R&D recognized for pioneering the use of artificial intelligence (AI) and bioinformatics for precision medicine, to support VERAXA's growing BiTAC pipeline of t cell engagers (TCEs) and antibody drug conjugates (ADCs).
2026-07-13 07:00:00
ZURICH, SWITZERLAND – July 13, 2026 -- VE RAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven computational partner for modern R&D recognized for pioneering the use of artificial intelligence (AI) and bioinformatics for precision medicine, to support VERAXA's growing BiTAC® pipeline of t cell engagers (TCEs) and antibody drug conjugates (ADCs).
2026-07-10 16:05:00
ZURICH, SWITZERLAND - July 10, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA"), an emerging leader in designing novel cancer therapies, today announced the appointment of Carl von Halem as Interim Chief Financial Officer. He succeeds Torsten Bürgermeister. The company is currently in the final stages of discussions with a highly qualified successor who is expected to support VERAXA's next phase of expansion and operational growth.
Frequently Asked Questions
-
What is the current Veraxa Biotech Holding AG (VRXA) stock price?
-
Veraxa Biotech Holding AG(NASDAQ:VRXA) stock price is $1.9701 in the last trading session. During the trading session, VRXA stock reached the peak price of $27.36 while $1.7 was the lowest point it dropped to. The percentage change in VRXA stock occurred in the recent session was --1.99% while the dollar amount for the price change in VRXA stock was -$0.04.
-
VRXA's industry and sector of operation?
-
The NASDAQ listed VRXA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of VRXA?
-
Christoph Antz | Co-Founder, Lead Director & CEO
Christoph Erkel | Vice President of Research & Development
Heinz Schwer | Chief Business Officer
Rick Austin | Chief Scientific Officer
Torsten Bürgermeister | Chief Financial Officer -
How many employees does VRXA have?
-
Number of VRXA employees currently stands at 8. VRXA operates from Im Neuenheimer Feld 584, Heidelberg, ZH 69120, DE.
-
Link for VRXA official website?
-
Official Website of VRXA is: https://www.veraxa.com
-
How do I contact VRXA?
-
VRXA could be contacted at phone #49 6221 3521330 and can also be accessed through its website. VRXA operates from Im Neuenheimer Feld 584, Heidelberg, ZH 69120, DE.
-
How many shares of VRXA are traded daily?
-
The average number of VRXA shares traded daily for last 3 months was 418.16K.
-
What is the market cap of VRXA currently?
-
The market value of VRXA currently stands at $278.59M with its latest stock price at $1.9701